Entrada Therapeutics (TRDA) Financials

Entrada Therapeutics (NASDAQ: TRDA) remains a cash-rich clinical-stage biotech, but the latest numbers show a business still far from profitability and now burning through its balance sheet faster than it was a year ago.

For Q1 2026, Entrada reported just $875,000 in revenue against $43.2 million in operating expenses, producing an operating loss of $42.3 million and a net loss of $40.1 million. The company’s cash position is still solid, but the trend is moving in the wrong direction as quarterly operating cash burn remains elevated.

• The company still has a substantial liquidity cushion, with $76.4 million in cash and $178.4 million in short-term investments at the end of Q1 2026.
• Total current assets of $266.9 million are far above current liabilities of $19.2 million, giving Entrada a strong near-term balance sheet.
• The company continues to generate meaningful cash from its investment portfolio, with $26.99 million in investing cash flow in Q1 2026, helped by $38.9 million of investment maturities/sales.
• Quarterly R&D spending has come down from prior peaks, which may indicate more controlled development spending than in 2024.
• Revenue is still modest and lumpy, with Q1 2026 sales of just $875,000, so results remain highly dependent on pipeline milestones and collaboration activity.
• The company is still funded largely by its investment portfolio rather than operating cash generation, which is typical for an early-stage biotech but means ongoing execution matters a lot.
• Weighted average shares outstanding have been relatively stable recently, suggesting limited dilution in the latest quarter.
• Operating cash flow was a steep negative $41.7 million in Q1 2026, showing the core business is still consuming a large amount of cash.
• Cash and equivalents fell from $93.3 million in Q3 2025 to $76.4 million in Q1 2026, while short-term investments also dropped sharply from $233.6 million to $178.4 million.
• The revenue base has weakened dramatically from early 2024 levels, when quarterly revenue was much higher, underscoring the volatility of Entrada’s business model.

Looking at the bigger picture, Entrada’s revenue has been highly uneven over the last several years: it posted strong quarters in 2024, but 2025 and early 2026 have seen a sharp pullback. That has not been matched by a meaningful reduction in expenses, so losses remain large.

Balance sheet leverage is also something investors should watch. While current liabilities are low, the company carries $45.5 million in capital lease obligations in noncurrent liabilities, and retained earnings remain deeply negative at negative $312.8 million, reflecting years of cumulative losses.

Bottom line: Entrada Therapeutics has enough cash and investments to keep operating for now, but the latest quarter shows continued heavy losses, weak revenue, and ongoing cash burn. For retail investors, the key questions are whether the pipeline can produce durable revenue and whether management can slow the burn rate before liquidity becomes a bigger concern.